HER2 Status in Gastric Cancer Metastases
Author Information
Author(s): Bozzetti C, Negri F V, Lagrasta C A, Crafa P, Bassano C, Tamagnini I, Gardini G, Nizzoli R, Leonardi F, Gasparro D, Camisa R, Capelli S, Silini E M, Ardizzoni A
Primary Institution: Azienda Ospedaliero-Universitaria, Parma, Italy
Hypothesis
Is HER2 status in metastatic sites of gastric carcinoma different from that in primary tumors?
Conclusion
The high concordance observed between HER2 results suggests that in gastric cancer, HER2 status is usually unchanged during the metastatic process.
Supporting Evidence
- Concordance of FISH results was 98.5%.
- Concordance of IHC results was 94.9%.
- Only one case showed discordance between primary tumor and metastasis.
Takeaway
This study looked at how HER2, a protein that can affect cancer growth, behaves in both the original and spread parts of stomach cancer, finding that it usually stays the same.
Methodology
HER2 status was assessed by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in 72 secondary lesions of gastric adenocarcinoma and in the corresponding primary tumours.
Potential Biases
Potential bias due to the small sample size and the reliance on specific assessment techniques.
Limitations
The study had a low number of cases analyzed, which limits the ability to draw broader conclusions.
Participant Demographics
{"gender_distribution":{"male":50,"female":22},"age_range":"49-88","intervention_type":{"surgical_resection":58,"biopsy":14},"primary_tumor_site":{"gastroesophageal_junction":6,"other":66}}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website